NewTimeSpace (newtimespace.com) News, June 24, 2026, PANGAEA CONNECT(01473.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 2.23 billion, increased by 4.77% YoY
NewTimeSpace (newtimespace.com) News, June 24, 2026, GOLD PEAK(00040.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 7.02 billion, increased by 2.52% YoY
NewTimeSpace (newtimespace.com) News,June 24, 2026, KARRIE INT'L(01050.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 3.47 billion, increased by 7.37% YoY
NewTimeSpace News: Phancy Group Co., Ltd. announced on June 24 that pursuant to its H-share Restricted Share Unit Scheme, the trustee acquired 700,000 H-shares on-exchange between June 22 and June 24, 2026, at an average price of HK$26.49 per share, with a total consideration of around HK$18.54 million.
NewTimeSpace News: HUTCHMED announced on June 25 that results from its pivotal Phase II registrational study of fisogatinib for the treatment of intrahepatic cholangiocarcinoma are set to be unveiled at the 2026 ESMO Gastrointestinal Cancers Congress.
NewTimeSpace News: Mabwell announced on June 24 that the clinical trial application for its self-developed Injection 9MW5211 for the indication of multiple sclerosis (MS) has been approved by the National Medical Products Administration (NMPA).
NewTimeSpace News: SG Group Holdings announced via an announcement dated June 24 that the Company has appointed Sky Pillar Capital Limited as its independent financial adviser to advise the independent board committee and independent shareholders in connection with the offer matters.
NewTimeSpace News: Shanxi Installation announced on June 24 that the second tranche of its 2026 publicly offered corporate bonds targeted at professional investors has been fully issued, with an actual issuance size of RMB 350 million and a coupon rate of 2.37%.
NewTimeSpace News: CIG SHANGHAI CO., LTD. announced on June 24 that the cumulative deviation in closing price increase of its A-shares has reached 20% across three consecutive trading days from June 22 to June 24, triggering abnormal price fluctuation. After verification, Cambridge Industries Group confirmed there are no material matters that ought to be disclosed but have not yet been announced.
NewTimeSpace News: UNI-BIO SCIENCE GROUP LIMITED announced on June 24 that the company has granted an aggregate of 300 million share options to four eligible participants at an exercise price of HK$0.09 per share.
NewTimeSpace News: Dobot Technology announced via an announcement dated June 24 that the company has authorised its trustee to purchase H-shares from the secondary market at an aggregate total consideration not exceeding HK$200 million pursuant to its H-share incentive scheme, to satisfy future award grants under the scheme.
NewTimeSpace News: Seyond Holdings Ltd. announced on June 25 that shareholders Honour Key Limited and Glory Summer Worldwide Limited have voluntarily entered into a lock-up commitment. Between June 25, 2026 and December 9, 2026, they will not dispose of their combined holding of approximately 148 million shares via secondary market bidding transactions at a price below HK$10 per share.
NewTimeSpace News: Antengene disclosed in an announcement on June 25 that its board of directors resolved to repurchase shares worth a maximum of HK$50 million on the open market funded by internal resources, in accordance with the share repurchase general mandate approved at the annual general meeting.
BIOSYSEN (01355.HK) plans to conduct a rights issue on the basis of \"2 for 1\", with estimated net proceeds of HKD 39 million.
Sirnaomics (2257.HK) announced that its executive director and chairman Dr. Patrick Lu purchased an aggregate of 20,300 ordinary shares on the open market on June 24, 2026, at an average price of approximately HK$5.00 per share using personal funds, bringing his total interest to 17,685,996 shares, representing 16.12% of total issued share capital. Dr. Lu expressed full confidence in the Group's development prospects and potential growth, and does not rule out further increasing his shareholding at an appropriate time subject to applicable laws and regulations.
Hanx Biopharmaceuticals (3378.HK) announced that all controlling shareholders have voluntarily extended their lock-up period by 12 months to December 22, 2027, undertaking not to reduce holdings in any manner; certain pre-IPO shareholders extended by 6 months to June 22, 2027, and certain cornerstone investors extended by 7 months to January 22, 2027. Cai Zhang Biotech and two other controlling shareholders collectively hold approximately 76.14 million shares, while seven pre-IPO investors including Beijing Longpan collectively hold approximately 25.05 million shares. The Company believes the extensions demonstrate shareholders' confidence in future prospects, core technology, and long-term value, with potential for further extensions based on business development.
